Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Gliosarcoma × Immunotherapy, Adoptive × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma, Non-Hodgkin 6 Recurrence 4 Lymphoma, Follicular 3 Lymphoma, B-Cell 3 Lymphoma 3 Leukemia, Myeloid, Acute 3 Leukemia 3 Burkitt Lymphoma 3 Neoplasm, Residual 2 Multiple Myeloma 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioma 2 Glioblastoma 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Stomach Neoplasms 1 Solid Tumors 1 Simpson-Golabi-Behmel syndrome 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Pleural Effusion, Malignant 1 Platinum-Resistant Ovarian Carcinoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1

Interventions

Temozolomide 44 Radiotherapy 25 Radiation 13 O(6)-benzylguanine 7 Irinotecan 7 Chemotherapy, Adjuvant 7 Erlotinib Hydrochloride 6 Carmustine 6 motexafin gadolinium 5 Surgical Procedures, Operative 5 Imatinib Mesylate 5 sargramostim 4 Radiotherapy, Intensity-Modulated 4 Magnetic Resonance Spectroscopy 4 Hydroxyurea 4 Gene Expression Profiling 4 Radiotherapy, Conformal 3 Immunohistochemistry 3 Genetic Therapy 3 Filgrastim 3 Drug Therapy 3 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3 vandetanib 2 lonafarnib 2 cediranib 2 Specimen Handling 2 Sorafenib 2 Radiosurgery 2 Nivolumab 2 Mass Spectrometry 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02664363 2023-02-17

ExCeL

Duke University

Phase 1 Terminated

3 enrolled 8 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡